Severe Asthma Clinical Trial Pipeline Analysis: 30+ Key Companies Shaping the Future of Severe Asthma Therapeutics | DelveInsight

DelveInsight's Severe Asthma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Severe Asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Severe Asthma pipeline domain.

Key takeaways from the Severe Asthma Clinical Trial Landscape Report
• DelveInsight's Severe Asthma pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Severe Asthma treatment.
• Key Severe Asthma companies such as AstraZeneca, Sanofi, Regeneron Pharmaceuticals, GSK, Teva Pharmaceutical Industries, Amgen, Roche, Novartis, and others
• Promising Severe Asthma pipeline therapies in various stages of development include Tezepelumab, Dupilumab, Benralizumab, Astegolimab, and others

Request a sample and discover the recent advances in Severe Asthma treatment drugs at: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Severe Asthma?
Severe Asthma is a chronic form of asthma characterized by persistent symptoms, frequent exacerbations, and reduced lung function despite high-dose inhaled corticosteroids and additional controller therapies. It is associated with airway inflammation, bronchial hyperresponsiveness, and airflow limitation. The symptoms include breathlessness, wheezing, chest tightness, and coughing. The treatment involves inhaled therapies, biologics, and systemic corticosteroids. The causes are associated with immune dysregulation and environmental triggers. The diagnosis is based on clinical examination, pulmonary function tests, biomarker analysis, and patient history.

Emerging Severe Asthma Drug Profiles

Tezepelumab: AstraZeneca/Amgen
Tezepelumab is a first-in-class thymic stromal lymphopoietin (TSLP) inhibitor designed to block upstream inflammatory pathways involved in asthma pathogenesis. Its active mechanism targets epithelial cytokines, reducing airway inflammation and exacerbation rates. The therapy is administered subcutaneously and has demonstrated efficacy across a broad population of severe asthma patients.

Dupilumab: Sanofi/Regeneron Pharmaceuticals
Dupilumab is a monoclonal antibody targeting IL-4 and IL-13 signaling pathways, key drivers of type 2 inflammation in severe asthma. It is administered via subcutaneous injection and is being evaluated across multiple clinical studies for its effectiveness in reducing exacerbations and improving lung function.

Learn more about the novel and emerging Severe Asthma pipeline therapies at: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Severe Asthma Clinical Trial Landscape
• In March 2026, AstraZeneca announced ongoing clinical progress with Tezepelumab in Severe Asthma, highlighting continued evaluation across patient populations.
• In February 2025, Sanofi and Regeneron Pharmaceuticals reported continued clinical development of Dupilumab for Severe Asthma, focusing on long-term outcomes and efficacy across diverse patient groups.
• In April 2026, GSK reported continued advancement of Benralizumab in patients with Severe Asthma, highlighting encouraging efficacy signals in ongoing studies.
• In March 2026, Roche announced ongoing clinical development activities for its Severe Asthma pipeline candidates, focusing on advancing targeted therapies across early and mid-stage trials.
• In February 2026, Novartis provided updates on Severe Asthma pipeline therapies, indicating continued enrollment and evaluation in clinical trials.
Scope of the Severe Asthma Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Inhalation
• Therapeutics Assessment By Molecule Type: Recombinant proteins, Small molecule, Monoclonal antibody, Peptide, Gene Therapy
• Key Severe Asthma Companies: AstraZeneca, Sanofi, Regeneron Pharmaceuticals, GSK, Teva Pharmaceutical Industries, Amgen, Roche, Novartis, and others
• Key Severe Asthma Pipeline Therapies: Tezepelumab, Dupilumab, Benralizumab, Astegolimab, and others

Dive deep into rich insights for new drugs for Severe Asthma treatment, visit https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Severe Asthma Pipeline Report Introduction
2. Severe Asthma Pipeline Report Executive Summary
3. Severe Asthma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Severe Asthma Pipeline Therapeutics
6. Severe Asthma Pipeline: Late Stage Products (Pre-registration)
7. Severe Asthma Pipeline: Late Stage Products (Phase III)
8. Severe Asthma Pipeline: Mid Stage Products (Phase II)
9. Severe Asthma Pipeline: Early Stage Products (Phase I)
10. Severe Asthma Pipeline Therapeutics Assessment
11. Inactive Products in the Severe Asthma Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Severe Asthma Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Severe Asthma pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.